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Vascular dysfunction associated with two-kidney, one-clip (2K-1C) hypertension may result from both
altered matrix metalloproteinase (MMP) activity and higher concentrations of reactive oxygen species
(ROS). Doxycycline is considering the most potent MMP inhibitor of tetracyclines and attenuates 2K-
1C hypertension-induced high blood pressure and chronic vascular remodeling. Doxycycline might also
act as a ROS scavenger and this may contribute to the amelioration of some cardiovascular diseases asso-
ciated with increased concentrations of ROS. We hypothesized that in addition to its MMP inhibitory
effect, doxycycline attenuates oxidative stress and improves nitric oxide (NO) bioavailability in 2K-1C
hypertension, thus improving hypertension-induced arterial endothelial dysfunction. Sham operated or
2K-1C hypertensive rats were treated with doxycycline 30 mg/kg/day (or vehicle). After 8 weeks of treat-
ment, aortic rings were isolated to assess endothelium dependent vasorelaxation to A23187. Arterial and
systemic levels of ROS were respectively measured using dihydroethidine (DHE) and thiobarbituric acid
reactive substances (TBARS). Neutrophils-derived ROS were tested in vitro using the ﬂuoroprobe Carboxy-
H2DCFDA and human neutrophils stimulated with phorbol 12-myristate 13-acetate (PMA). NO levels
were assessed in rat aortic endothelial cells by confocal microscopy. Aortic MMP activity was determined
by in situ zymography. Doxycycline attenuated 2K-1C hypertension (169 ± 17.3 versus 209 ± 10.9 mm Hg
in hypertensive controls, p < 0.05) and protected against hypertension-induced reduction in endothe-
lium-dependent vasorelaxation to A23187 (p < 0.05). Doxycycline also decreased hypertension-induced
oxidative stress (p 6 0.05), higher MMP activity (p < 0.01) and improved NO levels in aortic endothelial
cells (p < 0.01). Therefore, doxycycline ameliorates 2K-1C hypertension-induced endothelial dysfunction
in aortas by inhibiting oxidative stress generation and improving NO bioavailability, in addition to its
inhibitory effects on MMP activity.
 2012 Elsevier Inc. Open access under the Elsevier OA license.Introduction
Hypertension is a worldwide health issue that is highly related
to vascular dysfunction and chronic vascular remodeling [1–3].
Since the endothelium plays an essential role in the arterial tone
regulation, its damage notably contributes to hypertension
-induced vascular alterations [4]. Increased levels of reactive oxy-
gen species (ROS) are implicated as a major cause of endothelial
dysfunction associated with both clinical and experimental hyper-
tension [5,6]. In this respect, lower nitric oxide (NO) bioavailability
and increased matrix metalloproteinases (MMPs) activation have
usually been described as important downstream effects of ROS-
induced vascular endothelial damage in hypertension [7,8].tos).
evier OA license.MMPs are a family of zinc-dependent endopeptidases widely
known as their ability to degrade extracellular matrix proteins.
HigherMMP-2 and -9 activities are found in plasma from hyperten-
sive patients [9,10] and in the arteries from hypertensive animals
(both in vascular smooth muscle and endothelial cells) [11–17]. In-
creased MMPs activities lead to excessive vascular smooth muscle
cells migration and proliferation as well as monocyte inﬁltration
into the arterial intima [18,19]. These effects may contribute to
hypertension-induced endothelial damage and maladaptive vascu-
lar remodeling.
The activity of MMPs can be regulated at multiple levels includ-
ing gene transcription, post-translational modiﬁcation and by
interaction with their endogenous tissue inhibitors (TIMPs).
Peroxynitrite (ONOO), an important ROS generated by the reaction
between superoxide and NO, induces post-translational modiﬁca-
tions of MMP activity [20,21]. In vitro, peroxynitrite at very high
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ical cysteine residue in MMP-2 propeptide domain and the zinc ion
in the catalytic site. This results in the active 72 kDa MMP-2 [21]. It
was also shown that increased arterial ROS generation may be a
downstream effect of increased MMP activity [22]. This interplay
between ROS and MMPs may promote a constant cause-effect cy-
cle. Some ROS per se also have oxidizing properties that are directly
responsible for hypertension-induced vascular dysfunction [7]. Fur-
thermore, since NO and superoxide react to produce ONOO, the
latter notably reduces vascular NO bioavailability and then contrib-
utes to hypertension-induced endothelial damage.
MMP inhibitorsmay be key pharmacological tools to prevent the
cardiovascular alterations associated with hypertension. Indeed,
doxycycline is considered the most potent MMP inhibitor of tetra-
cyclines and inhibits MMP activity independently of its antimicro-
bial effect [23,24]. Studies using animal models of hypertension
have shown that doxycycline attenuates both the high blood pres-
sure and the chronic vascular remodeling found in hypertension,
probably as a result of MMPs inhibition [11,15–17,25]. We have
also shown that doxycycline ameliorates 2K-1C-hypertension-in-
duced impaired endothelial-dependent vasorelaxation, arterial
wall hypertrophy and excessive collagen/elastin deposition
[15,26]. However, doxycyclinemay also act as a ROS scavenger drug
[27–29]. This drug reduced doxorubicin-induced ROS production in
mice heart and also myocardial cell apoptosis, thus attenuating
ventricular remodeling and systolic dysfunction [27]. Similar ef-
fects on ROS levels were also observed in testes of mice treatedwith
doxorubicin [28]. Moreover, oral treatment of spontaneous hyper-
tensive rats with doxycycline reduced the microvascular oxidative
stress and lessened the proteolytic degradation of insulin receptor
in leukocytes [30]. Doxycycline may also inhibit ROS derived from
neutrophils in vitro [31] and hypochloride-induced collagenase
activation in osteoblast-like cells [32]. However, there are no stud-
ies showing whether treatment with doxycycline decreases 2K-1C
hypertension-induced vascular ROS production (in addition to its
MMP inhibitory effect) and if this effect contributes to improve
the impaired endothelial-dependent vasorelaxation and arterial
wall hypertrophy.
In the present study, we addressed the hypothesis that although
doxycycline inhibits MMP activity, it may also ameliorate 2K-1C
hypertension-induced endothelial dysfunction by attenuating oxi-
dative stress. We used the 2K-1C hypertension model as it is asso-
ciated with enhanced MMP activity and oxidative stress as well as
signiﬁcant vascular dysfunction.Methods
Animals and treatments
This study complied with guidelines of Faculty of Medicine of
Ribeirão Preto, University of São Paulo. Animals were handled
according to guiding principles published by the National Insti-
tutes of Health (NIH). Male Wistar rats (180–200 g) obtained from
the colony at University of São Paulo were maintained on 12-h
light/dark cycle at room temperature (22–25 C) with free access
to standard chow and water.
The 2K-1C hypertension model was induced by clipping the left
renal artery with a silver clip (0.2 mm). Sham-operated rats under-
went the same surgical procedure (anesthesia with ketamine
100 mg/kg and xylazine 10 mg/kg i.p.) except for the clip placement.
Animals were randomly assigned to one of four groups: 2K-1C and
Sham that received tap water and 2K-1C and Sham that received
doxycycline at 30 mg/kg/day by gavage. It was previously showed
that this dose inhibitsMMP activity in vivo [11,15,17,26]. Treatment
was started two weeks after surgery and maintained for eightweeks. Tail systolic blood pressure (SBP) was assessed weekly by
tail-cuff plethysmography. Plasma and aortas were removed from
rats previously treated with doxycycline at 30 mg/kg/day to per-
form all the ex vivo experiments presented here.
Vascular reactivity
After 8 weeks of treatment, thoracic aortas were isolated and
cleaned of connective tissue and fat. Aortic rings were cut at
4 mm in length and placed in organ chambers containing modiﬁed
Krebs salt solution of the following composition (mM): NaCl 130,
CaCl2 1.6, MgSO4 1.2, KH2PO4 1.2, KCl 4.7, NaHCO3 14.9, glucose
5.5, which was maintained at 37 C, pH 7.4, and bubbled with 95%
O2 and 5% CO2. The systemwas connected to an isometric force dis-
placement transducer (Letica Scientiﬁc Instruments; Barcelona,
Spain) and aortic responses were recorded on a computer system
using Chart V4.04, PowerLab AD Instruments (2000) Program. Aor-
tic rings were submitted to a tension of 1.5 g during 60 min equili-
bration period and were considered to have an intact functional
endothelium when acetylcholine (1 lM) produced a relaxation of
more than 80%. Relaxation was calculated as a percentage of con-
traction induced by phenylephrine (100 nM). To assess endothe-
lium-dependent vasorelaxation, aortic rings pre-contracted with
phenylephrine (100 nM) were used to construct a cumulative con-
centration–response curve to the calcium ionophore A23187
(1 nM–1 lM) [33].
Measurement of aortic ROS and plasma lipid peroxide levels
Dihydroethidium (DHE), a sensitive superoxide probe, was used
to evaluate in situ production of ROS in aortas. Brieﬂy, aortic tissues
were vertically embedded in an OCT compound and were frozen
and cut in serial 4 lm sections. Unﬁxed cryosections were incu-
bated in dark, at room temperature, with DHE at 10 lM for
30 min. Sections were examined with a ﬂuorescence microscope
(Leica Imaging Systems Ltd., Cambridge, England) and images were
captured at X40. Red ﬂuorescence represents superoxide produc-
tion. The intensity of ﬂuorescent signal was evaluated by using Im-
ageJ Program (NIH). We measured it from 20 ﬁelds selected around
the vessel circumference, and the arithmetic mean of the ﬂuores-
cence from 20 ﬁelds was calculated for each slide [8].
Plasma lipid peroxide levels were determined by measuring
thiobarbituric acid reactive substances (TBARS) using a ﬂuoromet-
ric method. Lipid peroxide levels were expressed in nmol/ml and in
terms of malondialdehyde (MDA). This method requires excitation
at 515 nm and emission at 553 nm and uses 1,1,3,3-tetramethoxy-
propane as standard [8].
Measurement of neutrophils-derived ROS in vitro
We also tested whether doxycycline inhibits neutrophils-
derived ROS in vitro. Brieﬂy, human neutrophils (1  106 cells/ml)
were isolated and plated into a sterile 96-well opaque microtiter
plate (200 lL/well). Cells were loaded with 5 lM of the ﬂuorop-
robe Carboxy-H2DCFDA (Molecular Probes, Oregon, USA) during
15 min at 37 C and, then, washed three times with Hanks modi-
ﬁed buffer. These cells were equilibrated during 5–10 min, treated
or not with different concentrations of doxycycline (0.8–200 lM)
and then incubated at 37 C with 5% CO2 for 30 min. Cells were
stimulated with phorbol 12-myristate 13-acetate (PMA) at
100 nM and plates were immediately placed into a spectroﬂuo-
rometer at 37 C (Gemini EM, Molecular Devices, Sunnyvale, CA).
Readings were recorded every 1–120 min. Carboxy-H2DCFDA re-
quires excitation at 495 nm and emission at 529 nm. Results were
expressed as arbitrary units of ﬂuorescence.
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microscopy
The selective NO ﬂuorescent dye 4,5-diaminoﬂuorescein diace-
tate (DAF-2/DA) was used to detect NO levels in aortic endothelial
cells [34]. Brieﬂy, rat thoracic aortas were quickly removed, longi-
tudinally opened and then were maintained in Hanks solution with
the following composition (mM): NaCl 145.0, CaCl2 1.6, KCl 5.0,
MgCl2 1.0, NaH2PO4 0.5, dextrose 10.0 and HEPES 10.0. Endothelial
cells were isolated from the aorta inner surface by gentle rake fric-
tion in Hanks solution. Cell suspension was centrifuged at
1000 rpm for 5 min and then, cell pellet was suspended in 0.5 ml
of Hanks buffer. The suspension was placed on 10% poly-L-lysine
coated slide for 30 min in a humidiﬁed 37 C incubator with 5%
CO2. Then, cells were loaded with 5 lM DAF-2/DA during 20 min
and were examined in Hanks buffer with a confocal scanning laser
microscope (Leica TCS SP5). DAF-2/DA ﬂuorescence was excited
with 488 nm line of an argon ion laser and the emitted ﬂuores-
cence was measured at 515 nm. Time-course software was used
to capture images of cells at one second intervals (xyt) in the Live
Data Mode acquisition at 700 Hz and 1024  1024 pixel. The inten-
sity of ﬂuorescent signal in the endothelial preparation was evalu-
ated by the LSCM computer software. The initial ﬂuorescence
intensity (FI) value was obtained at t = 0 and it was designated
Fo. Final FI value obtained after stimulation with A23187 (1 lM)
was designated F. The percentage of difference in FI (% DFI), which
reﬂects increase of NO concentration in endothelial cells, was ob-
tained in relation to Fo (100%). It was calculated by the following
formula: %DFI = (F  Fo)/Fo  100.Measurement of aortic MMP activity by in situ zymography
MMP activity in frozen thoracic aortas was measured using DQ
Gelatin as a ﬂuorogenic substrate (E12055, Molecular Probes, Ore-
gon, USA). Aortic tissues were vertically embedded in OCT com-
pound and then frozen and cut in serial 4 lm sections. Vessels
sections were incubated in dark humidiﬁed chambers for 1 h with
1 lM DQ gelatin in Tris–CaCl2 buffer (Tris 50 mM, CaCl2 10 mM,
ZnCl2 1 lM). Sections were examined by a ﬂuorescent microscope
(Leica Imaging Systems Ltd., Cambridge, England) and images were
captured at 40. Proteolytic activity was detected as a bright green
ﬂuorescence, which indicates substrate degradation by MMPs, and
was evaluated using the ImageJ Program. The assessment of gela-
tinolytic activity was made by quantifying the intensity of ﬂuores-
cence from 20 ﬁelds selected around vessel circumference. The
arithmetic mean of the ﬂuorescence from 20 ﬁelds was calculated
for each slide [17]. Phenanthroline and PMSF, both at 1 mM, were
used to conﬁrm MMP activity. While phenanthroline inhibited
MMP activity, PMSF produced no major effects. Doxycycline
in situ at 0.1 mM produced no auto-ﬂuorescence interference (data
not shown).Statistical analysis
Results are expressed as mean + S.E.M. Between groups, com-
parisons were assessed by two-way analysis of variance (ANOVA)
using Bonferroni correction or t test as appropriate. Pearson corre-
lations and linear regression were calculated for Fig. 4 comparing
arbitrary units of ﬂuorescence resulted from PMA-stimulated ROS
production in neutrophils with increasing concentrations of doxy-
cycline (lM) (GraphPad Prism 5.01 software). A probability value
of 5% was considered signiﬁcant.Results
Doxycycline attenuates hypertension in 2K-1C rats
While no signiﬁcant changes in SBP were observed in Sham and
Sham + doxy groups, it was signiﬁcantly increased in 2K-1C rats
(p < 0.01). Doxycycline attenuated higher SBP in hypertensive rats
throughout the treatment (p < 0.05 effects for doxycycline in
hypertensive rats, but not in Sham groups, Fig. 1A) which conﬁrms
previous results of our group [15,17,26]. The following values show
SBP at 8 weeks of treatment (n = 8/group, in mmHg): Sham
103 ± 2.5, Sham + doxy 107 ± 5.2, 2K-1C 209 ± 10.9 and 2K-
1C + doxy 169 ± 17.3 (Fig. 1B).
Doxycycline ameliorates hypertension-induced endothelial
dysfunction in aortas
To evaluate the effect of doxycycline on 2K-1C hypertension-
induced arterial endothelial dysfunction, aortic rings were isolated
and their functional performance was assessed in organ chamber
experiments. Fig. 2 shows endothelial cell-dependent vasorelaxa-
tion induced by A23187 (1 nM–1 lM). 2K-1C hypertension showed
a signiﬁcant impairment of the maximum A23187-induced aorta
relaxation, thus reﬂecting endothelial dysfunction (⁄p < 0.01 versus
both Sham groups, Fig. 2). Although no apparent changes were
seen in Sham + doxy group, treatment with doxycycline signiﬁ-
cantly attenuated 2K-1C-induced impaired endothelial-dependent
vasorelaxation to A23187 which is related to its maximal relaxa-
tion response (⁄⁄p < 0.05 for doxycycline effects, Fig. 2).
Doxycycline reduces hypertension-induced oxidative stress
ROS production was ﬁrst evaluated in situ in isolated aortic seg-
ments by ﬂuorescence microscopy. We found increased ROS levels
distributed throughout the entire aorta of 2K-1C rats when com-
pared with Sham groups (⁄p < 0.05, Fig. 3A and B). Treatment with
doxycycline diminished 2K-1C-induced vascular oxidative stress.
Lipid peroxide levels were also determined by measuring TBARS
in plasma. We found increased plasma levels of MDA in 2K-1C rats
compared with Sham groups (⁄p < 0.05), an effect which was re-
versed by doxycycline treatment (⁄p 6 0.05, Fig. 3C).
Doxycycline attenuates neutrophils-derived ROS in vitro
To verify whether doxycycline inhibits neutrophils-derived
ROS, human neutrophils were treated or not with different
concentrations of doxycycline (0.8–200 lM) and then stimulated
with PMA. The arbitrary units of ﬂuorescence resulted from PMA-
stimulated ROS production in neutrophils correlated inversely
with increasing concentrations of doxycycline (p < 0.05,
r = 0.9234, Fig. 4). Cells that were treated either with PMA alone
or PMA plus lower concentrations of doxycycline showed higher
levels of ROS, as represented by the increased ﬂuorescence
intensity. However, neutrophils that were previously treated with
doxycycline at higher concentrations showed signiﬁcant reduction
in PMA-stimulated ROS production. The estimate half maximal
effective concentration (EC50) of doxycycline that inhibits neutro-
phils-derived ROS in vitro is approximately 181.3 lM.
Doxycycline protects against hypertension-induced loss of NO
bioavailability in aortic endothelial cells
NO levels in aortic endothelial cells were assessed at each one
second intervals by confocal microscope using the selective NO
ﬂuorescent dye DAF-2/DA. As shown in Fig. 5, NO production
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Fig. 1. Systolic blood pressure (SBP) after 8 weeks of hypertension. SBP (mmHg) was weekly measured by tail-cuff plethysmography in all experimental groups during the
study period (A). Bar graph represents the ﬁnal SBP in mmHg (B). Data are shown as mean ± S.E.M. (n = 8). ⁄p < 0.01 versus Sham and Sham + Doxy groups and #p < 0.05,
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groups, which was represented by lessening ﬂuorescence intensity
(⁄p < 0.01). Treatment with doxycycline markedly inhibited 2K-1C-
induced loss of NO bioavailability in aortic endothelial cells
(#p < 0.01 effects for doxycycline in hypertensive rats, but not in
Sham groups, Fig. 5).Doxycycline reduces increased MMP activity in aortas of 2K-1C
hypertensive rats
In situ zymography was used to assess MMP activity in frozen
cross-sectioned aortas. We found enhanced green ﬂuorescence
throughout the entire aorta including the endothelium of 2K-1C
rats compared with Sham groups (⁄p < 0.01, Fig. 6). Doxycycline
signiﬁcantly attenuated hypertension-induced higher MMP activ-
ity in entire aortas (#p < 0.01), although no changes in activity were
observed in Sham + doxy group.
By using two-way ANOVA it was possible to verify that there
are clearly interaction between Doxy and 2K-1C treatments in Figs.
1, 5 and 6.Discussion
Hypertension is associated with well known functional and
structural vascular alterations that may result from the interplayof several mechanisms. This study is the ﬁrst to show that doxycy-
cline decreases the oxidative stress in 2K-1C hypertension. This ef-
fect may contribute to the improvement of the vascular
dysfunction associated with hypertension, not only by decreasing
vascular MMP activity, but also by increasing NO bioavailability.
Similar to what we found in previous reports using rat aortas
[15,17,26], we showed here that treatment with doxycycline de-
creased higher MMP activity in the aortas from 2K-1C rats and sig-
niﬁcantly improved hypertension-induced impaired endothelial-
dependent vasorelaxation. Using in situ zymography, we observed
an important link between the localization of MMPs in hyperten-
sive aortic wall with the functional vascular alteration. The in-
creased MMP activity in the aortic endothelium of hypertensive
rats may be related to hypertension-induced vascular dysfunction,
and this association would not be detected if we assessed MMP
levels by conventional gelatin zymography using the whole aorta.
However, the mechanisms by which MMPs contribute to hyperten-
sion-induced vascular dysfunction still remain to be elucidated. It
is possible that MMP-induced excessive degradation of extracellu-
lar matrix and vascular smooth muscle cells migration from media
to intima layer contributes to such endothelial damage [18,35].
Moreover, it is possible that MMP-2-mediated vascular contractil-
ity by cleaving some peptides, such as big-endothelin-1 [36], calci-
tonin gene-related peptide [37] and adrenomedullin [38] also
contributes to endothelial dysfunction and increased vascular
resistance in hypertension.
Although non-antimicrobial effects of doxycycline are related to
MMP inhibition, both in vivo and in vitro studies have also shown
that this drug may have signiﬁcant ROS scavenging properties
[27–29,31,32]. In line with these ﬁndings, our results show for
the ﬁrst time that treatment with doxycycline reduced 2K-1C
hypertension-induced systemic and vascular oxidative stress. We
have also found that PMA-stimulated ROS production in neutro-
phils in vitro correlated inversely with increasing concentrations
of doxycycline. In addition, high concentrations of doxycycline
may also directly react with superoxide [39] and peroxynitrite
in vitro and these ﬁndings corroborate the idea that doxycycline
may be a potential ROS scavenger in hypertensive rats. In fact,
Fig. 3A and B shows that treatment of hypertensive rats with doxy-
cycline at 30 mg/kg/day decreased higher levels of superoxide in
aortas which was represented as DHE levels. Supporting our ﬁnd-
ings, a recent study in mice showed that doxycycline prevented
doxorubicin-induced myocardial ROS production, thus ameliorat-
ing the systolic dysfunction and detrimental ventricular remodel-
ing [27]. Similar effects on ROS production were also found in
testes of mice treated with doxorubicin [28].
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cular dysfunction found both in clinical and experimental hyper-
tension [5–8]. High levels of superoxide react with NO in the
aortic endothelium, thus reducing its bioavailability and leading
to endothelial dysfunction and impaired vascular relaxation. Our
results suggest that the protective effects of doxycycline against
2K-1C-induced vascular dysfunction may result of its action as a
ROS scavenger. In fact, we found that doxycycline decreased 2K-
1C-induced oxidative stress and protected against loss of NO bio-
availability in aortic endothelial cells, thus contributing to the
amelioration of hypertension-induced endothelial dysfunction. To
assess NO and endothelial-dependent vasorelaxation, we usedthe calcium ionophore A23187. This drug has the ability to move
calcium through cell membranes, thus inducing endothelial NO
production by diverse mechanisms [33]. Interestingly, doxycycline
improved NO levels in aortic endothelial cells from hypertensive
animals. Our ﬁndings are consistent with previous results showing
that doxycycline improved vascular dysfunction in mice with Mar-
fan syndrome [40]. The beneﬁcial effects of doxycycline were asso-
ciated with increased vascular endothelial NO synthase
phosphorylation and increased NO bioavailability [40]. Our ﬁnd-
ings suggest a potential additional effect of doxycycline that may
explain the how doxycycline improved the vascular function in
hypertension.
To reach circulating concentrations of doxycycline in rats simi-
lar to what it is observed in adult humans (approximately 4 lM
after a single oral dose of 100 mg [41]), rats were treated with a
relatively higher dose of doxycycline at 30 mg/kg/day as they have
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20 lm) probed with DQ gelatin and examined using a ﬂuorescent microscope. Panel B shows the quantiﬁcation of percentage of vessel surface area covered by bright green
ﬂuorescence, characterized by gelatinolytic activity. Phenanthroline 1 mM and PMSF 1 mM were used to conﬁrm MMP activity (data not shown). Data are shown as
mean ± S.E.M. (n = 5). ⁄p < 0.01 versus Sham groups and #p < 0.01, signiﬁcant effects for doxycycline in hypertensive rats, but not in Sham groups. (For interpretation of the
references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
M.M. Castro et al. / Nitric Oxide 26 (2012) 162–168 167more rapidly metabolism than humans. According to Prall et al.
[41], treatment of mice with oral doses of doxycycline at 10, 50
and 100 mg/kg produced dose-dependent increases in drug serum
concentrations of 1.4, 2.7 and 11.9 lg/ml which correspond to 2.7,
5.3 and 23.2 lM, respectively. If we consider that after oral admin-
istration of 30 mg/kg of doxycycline in rats, its serum concentra-
tion is proportional to what is observed in mice, we would
expect to see doxycycline concentration at approximately 4.2 lM
(which is closely related to what it is seen in humans after a single
dose of 100 mg doxycycline). Furthermore, since it was suggested
that diabetic rats orally treated with doxycycline at 15 mg/kg/
day contained 2 lM of it in plasma [42], we would expect to see
in our study a concentration of doxycycline around 4 lM (consid-
ering that the rat gender, specie and body weight in both studies
were similar). In addition to treat the rats with 30 mg/kg/day of
doxycycline, we also treated them with 3 and 10 mg/kg/day [26].
Using these lower doses, we did not observe any improvement in
MMP-induced vascular alterations in hypertension. A very likely
reason to explain this lack of effects is attributed to the insufﬁcient
concentrations of doxycycline that may reach rat aortas (probably
lower than 4 lM). According to Prall et al. [41], doxycycline at cir-
culating concentrations higher than 4 lM was signiﬁcantly effec-
tive in reducing MMPs-induced aortic aneurysm growth in mice.
This may explain why we observed improvement in MMP-induced
vascular dysfunction in hypertension using only doxycycline at 30,
but not 3 and 10 mg/kg/day. The resultant lower concentration of
doxycycline may also be a reason to justify that its lower doses
would not decrease the levels of either nitric oxide or ROS in
hypertensive rats (although there is a recent article showing that
doxycycline at very low-dose may restore diabetes-induced in-
crease in plasma lipid peroxidation [43]). However, this latter
hypothesis should be further investigated in hypertension.
Several studies have shown the important link between ROS
and MMPs [20–22,44]. The reaction of superoxide and NO in thevasculature promotes ONOO formation. This harmful ROS acti-
vates the 72 kDa MMP-2 by disrupting the binding between the
critical cysteine residue in its propeptide and the zinc ion in the
catalytic site [21,44]. In vitro studies have also shown that ROS
can enhance both MMP-2 mRNA levels and activity via increasing
vascular pro-oxidant enzymes activities [45,46]. Using antioxi-
dants, such as tempol, we recently showed in a in vivo study that
MMP-2 activity may be an important downstream mechanism of
ROS-induced vascular endothelial damage in 2K-1C hypertension
[8]. Conversely, it was also suggested that MMPs may be upstream
mediators of ROS generation. Using isolated rat mesenteric arter-
ies, the study showed that by inhibiting MMP activity, doxycycline
and GM6001 prevented arterial oxidative stress production and
decreased phenylephrine-induced enhances in vascular tone and
hypertrophy [22]. Because doxycycline inhibited 2K-1C-induced
oxidative stress and MMP activity in the present study, it is uncer-
tain whether increased ROS levels are responsible to trigger MMP
activation or whether MMPs mediate the generation of oxidative
stress, thus leading to hypertension-induced vascular changes.
Doxycycline directly inhibits MMP activity through its ability to
chelate the catalytic Zn2+ ion essential for MMP activity. In addi-
tion, as doxycycline contains phenol rings in its structure, it may
act as a ROS scavenger, thus decreasing several harmful effects in-
duced by oxidative stress [27–29]. However, because doxycycline
directly inhibits MMP activity and the deleterious effects of oxida-
tive stress may be partially mediated by MMP activation, labeling
doxycycline as antioxidant would be overstated.
In conclusion our results suggest that doxycycline ameliorates
2K-1C hypertension-induced arterial endothelial dysfunction in
part by inhibiting oxidative stress generation and improving NO
bioavailability, and these effects may contribute to MMP inhibition
to protect against the vascular alterations of hypertension. Since
there is a link between ROS and MMPs, and doxycycline may inhi-
bit both, it is unclear whether doxycycline-induced ROS reduction
168 M.M. Castro et al. / Nitric Oxide 26 (2012) 162–168potentiates its effect on MMP inhibition (or vice versa). Further
studies should be carried out to clarify this issue in hypertension.Acknowledgments
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